Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1999 Oct;52(10):719–722. doi: 10.1136/jcp.52.10.719

Biological consequences of the BCR/ABL fusion gene in humans and mice.

M Y Gordon 1
PMCID: PMC501561  PMID: 10674025

Full text

PDF
719

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albrecht T., Schwab R., Henkes M., Peschel C., Huber C., Aulitzky W. E. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol. 1996 Dec;95(3):501–507. doi: 10.1046/j.1365-2141.1996.d01-1934.x. [DOI] [PubMed] [Google Scholar]
  2. Amos T. A., Lewis J. L., Grand F. H., Gooding R. P., Goldman J. M., Gordon M. Y. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol. 1995 Oct;91(2):387–393. doi: 10.1111/j.1365-2141.1995.tb05308.x. [DOI] [PubMed] [Google Scholar]
  3. Bedi A., Barber J. P., Bedi G. C., el-Deiry W. S., Sidransky D., Vala M. S., Akhtar A. J., Hilton J., Jones R. J. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995 Aug 1;86(3):1148–1158. [PubMed] [Google Scholar]
  4. Bedi A., Zehnbauer B. A., Barber J. P., Sharkis S. J., Jones R. J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 1994 Apr 15;83(8):2038–2044. [PubMed] [Google Scholar]
  5. Brito-Babapulle F., Bowcock S. J., Marcus R. E., Apperley J., Th'ng K. H., Dowding C., Rassool F., Guo A. P., Catovsky D., Galton D. A. Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. Br J Haematol. 1989 Sep;73(1):76–81. doi: 10.1111/j.1365-2141.1989.tb00223.x. [DOI] [PubMed] [Google Scholar]
  6. Carlo-Stella C., Dotti G., Mangoni L., Regazzi E., Garau D., Bonati A., Almici C., Sammarelli G., Savoldo B., Rizzo M. T. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood. 1996 Oct 15;88(8):3091–3100. [PubMed] [Google Scholar]
  7. Clark S. S., Chen E., Fizzotti M., Witte O. N., Malkovska V. BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets. J Virol. 1993 Oct;67(10):6033–6046. doi: 10.1128/jvi.67.10.6033-6046.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Clarkson B. D., Strife A., Wisniewski D., Lambek C., Carpino N. New understanding of the pathogenesis of CML: a prototype of early neoplasia. Leukemia. 1997 Sep;11(9):1404–1428. doi: 10.1038/sj.leu.2400751. [DOI] [PubMed] [Google Scholar]
  9. Coggle J. E., Gordon M. Y. Quantitative measurements on the haemopoietic systems of three strains of mice. Exp Hematol. 1975 Jun;3(3):181–186. [PubMed] [Google Scholar]
  10. Daley G. Q., Van Etten R. A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990 Feb 16;247(4944):824–830. doi: 10.1126/science.2406902. [DOI] [PubMed] [Google Scholar]
  11. Dazzi F., Capelli D., Hasserjian R., Cotter F., Corbo M., Poletti A., Chinswangwatanakul W., Goldman J. M., Gordon M. Y. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. Blood. 1998 Aug 15;92(4):1390–1396. [PubMed] [Google Scholar]
  12. Dick J. E. Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol. 1996 Aug;8(4):197–206. doi: 10.1006/smim.1996.0025. [DOI] [PubMed] [Google Scholar]
  13. Eaves C. J., Cashman J. D., Wolpe S. D., Eaves A. C. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12015–12019. doi: 10.1073/pnas.90.24.12015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Eaves C. J., Eaves A. C. Stem cell kinetics. Baillieres Clin Haematol. 1997 Jun;10(2):233–257. doi: 10.1016/s0950-3536(97)80005-4. [DOI] [PubMed] [Google Scholar]
  15. Gishizky M. L., Johnson-White J., Witte O. N. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3755–3759. doi: 10.1073/pnas.90.8.3755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gordon M. Y., Blackett N. M. Reconstruction of the hematopoietic system after stem cell transplantation. Cell Transplant. 1998 Jul-Aug;7(4):339–344. doi: 10.1177/096368979800700401. [DOI] [PubMed] [Google Scholar]
  17. Gordon M. Y., Blackett N. M. Some factors determining the minimum number of cells required for successful clinical engraftment. Bone Marrow Transplant. 1995 May;15(5):659–662. [PubMed] [Google Scholar]
  18. Gordon M. Y., Dazzi F., Marley S. B., Lewis J. L., Nguyen D., Grand F. H., Davidson R. J., Goldman J. M. Cell biology of CML cells. Leukemia. 1999 Apr;13 (Suppl 1):S65–S71. doi: 10.1038/sj.leu.2401281. [DOI] [PubMed] [Google Scholar]
  19. Gordon M. Y., Dowding C. R., Riley G. P., Goldman J. M., Greaves M. F. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature. 1987 Jul 23;328(6128):342–344. doi: 10.1038/328342a0. [DOI] [PubMed] [Google Scholar]
  20. Gordon M. Y., Goldman J. M. Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment. Br J Haematol. 1996 Oct;95(1):10–20. [PubMed] [Google Scholar]
  21. Gordon M. Y., Lewis J. L., Marley S. B., Grand F. H., Goldman J. M. Stromal cells negatively regulate primitive haemopoietic progenitor cell activation via a phosphatidylinositol-anchored cell adhesion/signalling mechanism. Br J Haematol. 1997 Mar;96(3):647–653. [PubMed] [Google Scholar]
  22. Gordon M. Y., Marley S. B., Lewis J. L., Davidson R. J., Nguyen D. X., Grand F. H., Amos T. A., Goldman J. M. Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J Clin Invest. 1998 Aug 15;102(4):710–715. doi: 10.1172/JCI3094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Grand F. H., Marley S. B., Chase A., Titley I., Healy L., Spencer A., Reiter A., Goldman J. M., Gordon M. Y. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients. Leukemia. 1997 Sep;11(9):1486–1492. doi: 10.1038/sj.leu.2400748. [DOI] [PubMed] [Google Scholar]
  24. Hariharan I. K., Harris A. W., Crawford M., Abud H., Webb E., Cory S., Adams J. M. A bcr-v-abl oncogene induces lymphomas in transgenic mice. Mol Cell Biol. 1989 Jul;9(7):2798–2805. doi: 10.1128/mcb.9.7.2798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Honda H., Fujii T., Takatoku M., Mano H., Witte O. N., Yazaki Y., Hirai H. Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood. 1995 May 15;85(10):2853–2861. [PubMed] [Google Scholar]
  26. Kelliher M. A., McLaughlin J., Witte O. N., Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6649–6653. doi: 10.1073/pnas.87.17.6649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Krause D. S., Fackler M. J., Civin C. I., May W. S. CD34: structure, biology, and clinical utility. Blood. 1996 Jan 1;87(1):1–13. [PubMed] [Google Scholar]
  28. Lewis I. D., McDiarmid L. A., Samels L. M., To L. B., Hughes T. P. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood. 1998 Jan 15;91(2):630–640. [PubMed] [Google Scholar]
  29. Lichtin A. The ITP practice guideline: what, why, and for whom? Blood. 1996 Jul 1;88(1):1–2. [PubMed] [Google Scholar]
  30. Marley S. B., Lewis J. L., Scott M. A., Goldman J. M., Gordon M. Y. Evaluation of "discordant maturation' in chronic myeloid leukaemia using cultures of primitive progenitor cells and their production of clonogenic progeny (CFU-GM). Br J Haematol. 1996 Nov;95(2):299–305. doi: 10.1046/j.1365-2141.1996.d01-1910.x. [DOI] [PubMed] [Google Scholar]
  31. Nirsimloo N., Gordon M. Y. Progenitor cells in the blood and marrow of patients with chronic phase chronic myeloid leukaemia respond differently to macrophage inflammatory protein-1 alpha. Leuk Res. 1995 May;19(5):319–323. doi: 10.1016/0145-2126(94)00143-x. [DOI] [PubMed] [Google Scholar]
  32. Pear W. S., Miller J. P., Xu L., Pui J. C., Soffer B., Quackenbush R. C., Pendergast A. M., Bronson R., Aster J. C., Scott M. L. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998 Nov 15;92(10):3780–3792. [PubMed] [Google Scholar]
  33. Sawyers C. L., Gishizky M. L., Quan S., Golde D. W., Witte O. N. Propagation of human blastic myeloid leukemias in the SCID mouse. Blood. 1992 Apr 15;79(8):2089–2098. [PubMed] [Google Scholar]
  34. Sirard C., Lapidot T., Vormoor J., Cashman J. D., Doedens M., Murdoch B., Jamal N., Messner H., Addey L., Minden M. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood. 1996 Feb 15;87(4):1539–1548. [PubMed] [Google Scholar]
  35. Talpaz M., Kantarjian H., Kurzrock R., Trujillo J. M., Gutterman J. U. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med. 1991 Apr 1;114(7):532–538. doi: 10.7326/0003-4819-114-7-532. [DOI] [PubMed] [Google Scholar]
  36. Thiele J., Zirbes T. K., Lorenzen J., Kvasnicka H. M., Dresbach S., Manich B., Leder L. D., Niederle N., Diehl V., Fischer R. Apoptosis and proliferation (PCNA labelling) in CML--a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy. J Pathol. 1997 Mar;181(3):316–322. doi: 10.1002/(SICI)1096-9896(199703)181:3<316::AID-PATH771>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  37. Verfaillie C. M., Bhatia R., Miller W., Mortari F., Roy V., Burger S., McCullough J., Stieglbauer K., Dewald G., Heimfeld S. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood. 1996 Jun 1;87(11):4770–4779. [PubMed] [Google Scholar]
  38. Verfaillie C. M. Chronic myelogenous leukemia: from pathogenesis to therapy. J Hematother. 1999 Feb;8(1):3–13. doi: 10.1089/106161299320523. [DOI] [PubMed] [Google Scholar]
  39. Verfaillie C. M., McCarthy J. B., McGlave P. B. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest. 1992 Oct;90(4):1232–1241. doi: 10.1172/JCI115985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Voncken J. W., Kaartinen V., Pattengale P. K., Germeraad W. T., Groffen J., Heisterkamp N. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood. 1995 Dec 15;86(12):4603–4611. [PubMed] [Google Scholar]
  41. Wang J. C., Lapidot T., Cashman J. D., Doedens M., Addy L., Sutherland D. R., Nayar R., Laraya P., Minden M., Keating A. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 1998 Apr 1;91(7):2406–2414. [PubMed] [Google Scholar]
  42. Zhang X., Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998 Nov 15;92(10):3829–3840. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES

  NODES
INTERN 1
twitter 2